Search

Your search keyword '"Carson, Peter"' showing total 714 results

Search Constraints

Start Over You searched for: Author "Carson, Peter" Remove constraint Author: "Carson, Peter"
714 results on '"Carson, Peter"'

Search Results

3. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials

5. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus

6. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

9. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2

10. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium

13. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development

14. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial

16. Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure

18. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

19. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation

20. MP-453090-7 IDENTIFYING PATIENTS WITH LVEF≤55% WHO MAY BENEFIT FROM A PRIMARY PREVENTION ICD USING SEATTLE PROPORTIONAL RISK MODEL FOR MILDLY REDUCED EF (SPRM-MR) IN 14,752 PATIENTS

21. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

24. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

25. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

26. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee

28. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee

30. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)

33. Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research

35. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure)

36. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)

37. Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee

38. Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee

39. Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure

41. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure

43. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

46. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

Catalog

Books, media, physical & digital resources